BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Machelska, H., & Celik, M. Ö. (2020). Immune cell-mediated opioid analgesia. Immunology letters, 227, 48–59. Added by: Dr. Enrique Feoli (15/05/2023, 20:32) Last edited by: Dr. Enrique Feoli (15/05/2023, 20:33) |
 |
| Resource type: Journal Article DOI: https://doi.org/10.1016/j.imlet.2020.08.005 ID no. (ISBN etc.): 0165-2478 BibTeX citation key: Machelska2020 View all bibliographic details  |
Categories: BioAcyl Corp, Zotero Subcategories: Analgesia Creators: Celik, Machelska Collection: Immunology letters |
Views: 3/144
|
| Abstract |
|
Pathological pain is regulated by a balance between pro-algesic and analgesic mechanisms. Interactions between opioid peptide-producing immune cells and peripheral sensory neurons expressing opioid receptors represent a powerful intrinsic pain control in animal models and in humans. Therefore, treatments based on general suppression of immune responses have been mostly unsuccessful. It is highly desirable to develop strategies that specifically promote neuro-immune communication mediated by opioids. Promising examples include vaccination-based recruitment of opioid-containing leukocytes to painful tissue and the local reprogramming of pro-algesic immune cells into analgesic cells producing and secreting high amounts of opioid peptides. Such approaches have the potential to inhibit pain at its origin and be devoid of central and systemic side effects of classical analgesics. In support of these concepts, in this article, we describe the functioning of peripheral opioid receptors, migration of opioid-producing immune cells to inflamed tissue, opioid peptide release, and the consequent pain relief. Conclusively, we provide clinical evidence and discuss therapeutic opportunities and challenges associated with immune cell-mediated peripheral opioid analgesia.
|